Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (641-650 of 869) with videos related to

Pageof 87
Sort By:
Blood|October 22, 2010
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myelomaMoshe E Gatt, Jian-Jun Zhao, Margaret S Ebert, et al.
British Journal of Haematology|April 10, 2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsKenji Ishitsuka, Teru Hideshima, Paola Neri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomibMelissa G Ooi, Patrick J Hayden, Vassiliki Kotoula, et al.
Blood|March 5, 2008
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Blood|April 13, 2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Teru Hideshima, et al.
Blood|December 23, 2006
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibGeorge Mulligan, Constantine Mitsiades, Barb Bryant, et al.
Cancer Immunology Research|November 2, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Blood|August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsSonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.
Blood|October 18, 2002
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaPaul G Richardson, Robert L Schlossman, Edie Weller, et al.
Blood|August 4, 2025
Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myelomaJoshua Rivera, Qi Yan, Saeed Daneshmandi, et al.
Pageof 87

Showing results (641-650 of 869) with videos related to

Sort By:
Pageof 87
Blood|October 22, 2010
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myelomaMoshe E Gatt, Jian-Jun Zhao, Margaret S Ebert, et al.
British Journal of Haematology|April 10, 2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsKenji Ishitsuka, Teru Hideshima, Paola Neri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomibMelissa G Ooi, Patrick J Hayden, Vassiliki Kotoula, et al.
Blood|March 5, 2008
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Blood|April 13, 2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Teru Hideshima, et al.
Blood|December 23, 2006
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibGeorge Mulligan, Constantine Mitsiades, Barb Bryant, et al.
Cancer Immunology Research|November 2, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Blood|August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsSonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.
Blood|October 18, 2002
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaPaul G Richardson, Robert L Schlossman, Edie Weller, et al.
Blood|August 4, 2025
Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myelomaJoshua Rivera, Qi Yan, Saeed Daneshmandi, et al.
Pageof 87